Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

ALK-negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects--a review.

ten Berge RL, Oudejans JJ, Ossenkoppele GJ, Meijer CJ.

J Pathol. 2003 May;200(1):4-15. Review.

PMID:
12692835
2.

CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features.

Stein H, Foss HD, Dürkop H, Marafioti T, Delsol G, Pulford K, Pileri S, Falini B.

Blood. 2000 Dec 1;96(12):3681-95. Review.

3.

Anaplastic large cell lymphoma, ALK-negative.

Ferreri AJ, Govi S, Pileri SA, Savage KJ.

Crit Rev Oncol Hematol. 2013 Feb;85(2):206-15. doi: 10.1016/j.critrevonc.2012.06.004. Epub 2012 Jul 11. Review.

4.

Anaplastic Large Cell Lymphoma.

Medeiros LJ, Elenitoba-Johnson KS.

Am J Clin Pathol. 2007 May;127(5):707-22. Review.

5.

Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma?

Fornari A, Piva R, Chiarle R, Novero D, Inghirami G.

Hematol Oncol. 2009 Dec;27(4):161-70. doi: 10.1002/hon.897. Review.

PMID:
19358142
6.

Systemic anaplastic large-cell lymphoma: results from the non-Hodgkin's lymphoma classification project.

Weisenburger DD, Anderson JR, Diebold J, Gascoyne RD, MacLennan KA, Müller-Hermelink HK, Nathwani BN, Ullrich F, Armitage JO.

Am J Hematol. 2001 Jul;67(3):172-8. Review.

7.

The t(2;5) in human lymphomas.

Kadin ME, Morris SW.

Leuk Lymphoma. 1998 Apr;29(3-4):249-56. Review.

PMID:
9684923
8.
9.

Cutaneous anaplastic large-cell lymphoma should be evaluated for systemic involvement regardless of ALK-1 status: case reports and review of literature.

Yang S, Khera P, Wahlgren C, Ho J, Jukic D, Geskin L, English JC.

Am J Clin Dermatol. 2011 Jun 1;12(3):203-9. doi: 10.2165/11537520-000000000-00000. Review.

PMID:
21366363
10.

Primary cutaneous and systemic anaplastic large cell lymphoma: clinicopathologic aspects and therapeutic options.

Querfeld C, Khan I, Mahon B, Nelson BP, Rosen ST, Evens AM.

Oncology (Williston Park). 2010 Jun;24(7):574-87. Review.

11.

Anaplastic lymphoma kinase proteins and malignancy.

Pulford K, Morris SW, Mason DY.

Curr Opin Hematol. 2001 Jul;8(4):231-6. Review.

PMID:
11561161
12.

[New concept for ALK negative anaplastic large cell lymphoma].

Tang XW, Shi XL, Wu DP.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011 Apr;19(2):511-6. Review. Chinese.

PMID:
21518520
13.

Anaplastic large cell lymphoma, ALK-positive.

Ferreri AJ, Govi S, Pileri SA, Savage KJ.

Crit Rev Oncol Hematol. 2012 Aug;83(2):293-302. doi: 10.1016/j.critrevonc.2012.02.005. Epub 2012 Mar 21. Review.

PMID:
22440390
14.

Need for an improved molecular/genetic classification for CD30+ lymphomas involving the skin.

Droc C, Cualing HD, Kadin ME.

Cancer Control. 2007 Apr;14(2):124-32. Review.

15.
16.

ALK-positive lymphoma: a single disease with a broad spectrum of morphology.

Benharroch D, Meguerian-Bedoyan Z, Lamant L, Amin C, Brugières L, Terrier-Lacombe MJ, Haralambieva E, Pulford K, Pileri S, Morris SW, Mason DY, Delsol G.

Blood. 1998 Mar 15;91(6):2076-84. Review.

17.

Anaplastic large cell lymphoma: a clinicopathologic analysis.

Skinnider BF, Connors JM, Sutcliffe SB, Gascoyne RD.

Hematol Oncol. 1999 Dec;17(4):137-48. Review.

PMID:
10725869
18.

[The many faces of anaplastic large cell lymphoma].

Foss HD, Marafioti T, Stein H.

Pathologe. 2000 Mar;21(2):124-36. Review. German.

PMID:
10840818
19.

Systemic and primary cutaneous anaplastic large cell lymphomas.

Kadin ME, Carpenter C.

Semin Hematol. 2003 Jul;40(3):244-56. Review.

PMID:
12876673
20.

Statistical evaluation of diagnostic and prognostic features of CD30+ cutaneous lymphoproliferative disorders: a clinicopathologic study of 65 cases.

Vergier B, Beylot-Barry M, Pulford K, Michel P, Bosq J, de Muret A, Beylot C, Delaunay MM, Avril MF, Dalac S, Bodemer C, Joly P, Groppi A, de Mascarel A, Bagot M, Mason DY, Wechsler J, Merlio JP.

Am J Surg Pathol. 1998 Oct;22(10):1192-202. Review.

PMID:
9777981
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk